News Sort by Year All Years 2024 (10) 2023 (28) 2022 (31) 2021 (33) 2020 (37) 2019 (7) 2018 (4) Search April 15, 2024 TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions March 28, 2024 TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results March 27, 2024 TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs March 25, 2024 TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting March 22, 2024 TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules March 20, 2024 TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules March 20, 2024 TFF Pharmaceuticals Announces Update on Clinical Programs March 14, 2024 TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024 January 24, 2024 TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference January 9, 2024 TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting